I recently challenged my investment research group to uncover a biotech stock that has positioned itself to be a market leader and/or a substantial innovator within a twenty-four month period. Our team screened over twenty potential candidates, some of whom have received recent market attention, and others that have been progressing in stealth mode. Three of the five team members converged on a small biotech company called Inovio Pharmaceuticals (INO). And, we agree that Inovio is about to lay comfortably at the end of the rainbow and swim in a pot of gold.
Inovio has certainly not been in stealth mode, and in fact, has been in a tug of war with both bulls and bears as to...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: